Eton Pharmaceuticals, Inc. ETON
We take great care to ensure that the data presented and summarized in this overview for Eton Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ETON
View all-
Opaleye Management Inc. Boston, MA2.86MShares$48.3 Million10.4% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.03MShares$34.3 Million3.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$22.7 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.18MShares$19.9 Million1.04% of portfolio
-
Morgan Stanley New York, NY586KShares$9.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA574KShares$9.7 Million0.0% of portfolio
-
Royal Bank Of Canada Toronto, A6479KShares$8.1 Million0.0% of portfolio
-
Westside Investment Management, Inc.473KShares$7.99 Million1.64% of portfolio
-
Cannell Capital LLC Alta, WY455KShares$7.7 Million3.23% of portfolio
-
State Street Corp Boston, MA438KShares$7.41 Million0.0% of portfolio
Latest Institutional Activity in ETON
Top Purchases
Top Sells
About ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Insider Transactions at ETON
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2025
|
James R. Gruber Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,542
-2.06%
|
$72,672
$16.99 P/Share
|
|
Dec 12
2025
|
David Krempa Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,264
-0.98%
|
$106,488
$17.0 P/Share
|
|
Dec 12
2025
|
Ipek Erdogan Trinkaus Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-3.42%
|
$1,360
$16.9 P/Share
|
|
Dec 12
2025
|
Sean Brynjelsen President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,732
-0.23%
|
$107,712
$16.83 P/Share
|
|
Aug 20
2025
|
James R. Gruber Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,631
-1.27%
|
$42,096
$16.02 P/Share
|
|
Aug 19
2025
|
James R. Gruber Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
39,082
-15.99%
|
$625,312
$16.16 P/Share
|
|
Jun 16
2025
|
David Krempa Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,223
-1.64%
|
$143,122
$14.73 P/Share
|
|
Jun 13
2025
|
David Krempa Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,800
-1.08%
|
$95,200
$14.77 P/Share
|
|
Jun 12
2025
|
David Krempa Chief Business Officer |
SELL
Open market or private sale
|
Direct |
16,977
-2.63%
|
$237,678
$14.92 P/Share
|
|
Jun 10
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,930
+1.76%
|
$118,950
$15.82 P/Share
|
|
Jun 05
2025
|
Sean Brynjelsen President & CEO |
SELL
Open market or private sale
|
Direct |
70,000
-2.38%
|
$1,120,000
$16.81 P/Share
|
|
Jun 04
2025
|
Sean Brynjelsen President & CEO |
SELL
Open market or private sale
|
Direct |
70,000
-2.32%
|
$1,190,000
$17.0 P/Share
|
|
Jun 03
2025
|
Sean Brynjelsen President & CEO |
SELL
Open market or private sale
|
Direct |
70,000
-0.76%
|
$1,260,000
$18.26 P/Share
|
|
Jan 03
2025
|
Norbert G Riedel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
102,400
+21.33%
|
$307,200
$3.61 P/Share
|
|
Oct 23
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.36%
|
$70,000
$7.98 P/Share
|
|
Oct 08
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
33,970
+2.84%
|
$237,790
$7.03 P/Share
|
|
Oct 07
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
11,248
+0.97%
|
$78,736
$7.22 P/Share
|
|
Oct 04
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,852
+1.45%
|
$101,112
$6.77 P/Share
|
|
Sep 11
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+3.94%
|
$200,000
$4.75 P/Share
|
|
Sep 10
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
57,500
+5.76%
|
$230,000
$4.65 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 7.93K shares |
|---|---|
| Exercise of conversion of derivative security | 102K shares |
| Payment of exercise price or tax liability | 17.6K shares |
|---|---|
| Open market or private sale | 286K shares |